Precision Medicine News and Research

RSS

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

AACR, IASLC sponsor conference on molecular origins of lung cancer

Lung cancer is the most commonly diagnosed cancer in the United States and often the most fatal unless caught early, but scientists are working on ways to improve their understanding of the disease. Several hundred of scientists will gather in San Diego at the San Diego Marriott Marquis & Marina during Jan. 8-11, 2012, for the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine.

6 Jan 2012

Itamar, Roche to further develop EndoPAT technology for pre-clinical trials

Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.

5 Jan 2012

SU2C, MRA announce new Dream Team dedicated to melanoma research

Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."

15 Dec 2011

GeneKey launches personalized medicine service for cancer patients

GeneKey Corp., announced today that it has launched a personalized medicine service that empowers cancer patients and their oncology teams to develop treatment strategies based on insight into the biology of individual tumors.

15 Dec 2011

Plexxikon announces scientific findings from PLX3397 preclinical studies on AML

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from preclinical studies showing that treatment with a novel oral agent, PLX3397, selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients.

13 Dec 2011

New gift to create Morsani College of Medicine building at USF Health

The University of South Florida has renamed its medical college the USF Health Morsani College of Medicine in honor of the philanthropic commitment of Frank and Carol Morsani. In total, the Morsanis have given $37 million to USF Health and a total of $43 million to the university.

12 Dec 2011

Northwestern researchers receive NIAMSD grant to study scleroderma

Northwestern Medicine researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study scleroderma, an autoimmune disease for which there currently is no cure.

2 Dec 2011

MergerTech launches $50M venture capital fund for healthcare IT

MergerTech Advisors is excited to announce the launch of 'MergerTech Capital', a new $50 million venture capital fund. The fund will focus on the investment and development of healthcare IT product and services firms, building on the sectors' substantial potential for extraordinary growth and creativity.

2 Dec 2011

Yale researchers monitor growth of laboratory-engineered blood vessels after implantation

Using magnetic resonance imaging (MRI) and nanoparticle technology, researchers from Yale have devised a way to monitor the growth of laboratory-engineered blood vessels after they have been implanted in patients. This advance represents an important step toward ensuring that blood vessels, and possibly other tissues engineered from a patient's own biological material, are taking hold and working as expected.

1 Dec 2011

AmberGen, SomaLogic enter licensing agreement for photocleavable biotin reagent

SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscan technology platform.

30 Nov 2011

Ambry Genetics deploys EMC Isilon scale-out NAS for gene sequencing

EMC Corporation today announced that Ambry Genetics, a leading commercial provider of clinical diagnostic and genomic services, has deployed EMC Isilon scale-out NAS to power its advanced gene sequencing operations, enabling Ambry to advance a range of scientific pursuits while easily managing 100 percent data growth annually.

30 Nov 2011

Second biopsy for suspected recurrent breast cancer can alter treatment

A second, larger clinical research study led by breast cancer specialists at Princess Margaret Hospital (PMH) has again proven that comparing a new biopsy of progressing or recurring cancer with that of the original cancer can dictate a change in treatment.

29 Nov 2011

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

29 Nov 2011

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

Roche establishes strategic alliance with Cedars-Sinai Medical Center

Roche announced today the establishment of a strategic alliance with Cedars-Sinai Medical Center in Los Angeles for the center to operate as a Roche Molecular Center of Excellence (MCOE) for the next five years.

From Roche Sequencing and Life Science 21 Nov 2011

Two genetic rearrangements may trigger 5 to 7% of breast cancers

Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.

20 Nov 2011

AMP announces Council's unanimous approval of strategic plan for personalized medicine

The Association for Molecular Pathology (AMP) today announced the AMP Council's unanimous approval of a strategic plan intended to guide the organization over the next four years.

19 Nov 2011

Scientists identify novel gene mutation that causes glioblastoma

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel gene mutation that causes at least one form of glioblastoma (GBM), the most common type of malignant brain tumor.

18 Nov 2011

China Medical Technologies second quarter net revenues increase 18.1% to RMB238.5 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the second fiscal quarter ended September 30, 2011 ("2Q FY2011") today.

18 Nov 2011